[1] |
Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study [J]. Kidney Int,2005,67(3): 1179-1187.
|
[2] |
Kidney Disease:Improving Global Outcomes (KDIGO) CKD-MBD Work Group.KDIGO clinical practice guideline for the diagnosis, evaluation, prevention and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)[J]. Kidney Int, 2009,76(1):S1-S130.
|
[3] |
Fukagawa M, Yokoyama K, Koiwa F, et al. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder[J]. Ther Apher Dial, 2013, 17(3): 247-288.
|
[4] |
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease[J]. Am J Kidney Dis, 2003, 42(4 Suppl 3): S1-S201.
|
[5] |
Yan Y, Qian J, Chen N, et al. Efficacy and initial dose determination of paricalcitol for treatment of secondary hyperparathyroidism in Chinese subjects [J]. Clin Nephrol, 2014, 81(1): 20-29.
|
[6] |
Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy [J]. N Engl J Med, 2003, 349(5): 446-456.
|
[7] |
Fukagawa M, Yumita S, Akizawa T, et al. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorous and calcium level in Japanese patients [J].Nephrol Dial Transplant,2008, 23(1):328-335.
|
[8] |
Block GA, Martin KJ, Francisco AL,et al.Cinacalcet for secondary hyperparathyroidism patients receiving hemodialysis [J].N Eng1 J Med,2004,350(15):1516-1525.
|
[9] |
Zitt E, Rix M, Fouque D, et al. Effectiveness of cinacalcet in patients with recurrent/persistent secondary hyperparathyroidism following parathyroidectomy: results of the ECHO study [J]. Nephrol Dial Transplant, 2011, 26(6):1956-1961.
|
[10] |
Ghani A, Baxter P.Surgical parathyroidectomy versus cinacalcet therapy:In the management of secondary hyperparathyroidism [J].Otolaryngol Head Neck Surg, 2012, 146(2): 220-225.
|
[11] |
Schneider R, Kolios G, Koch BM,et al. An economic comparison of surgical and medical therapy in patient with secondary hyperparathyroidism-the German perspective [J].Surgery, 2010, 148(6): 1091-1099.
|
[12] |
姚力,张凌等.甲状旁腺切除术治疗难治性甲状旁腺功能亢进症89例疗效评价[J].中国血液净化,2009,8(8):431-436.
|
[13] |
花瞻,姚力,张凌,等.肾性甲状旁腺功能亢进外科治疗术前高频彩超和99Tcm-MIBI双时相显像的应用[J]. 中国骨质疏松杂志,2010,16(8): 580-583.
|
[14] |
Shih ML, Duh QY, Hsieh CB, et al. Total parathyroidectomy without autotransplantation for secondary hyperparathyroidism [J]. World J Surg, 2009, 33(2): 248-254.
|
[15] |
Milas M, Weber C. Near-total parathyroidectomy is beneficial for patients with secondary and tertiary hyperparathyroidism [J]. Surgery, 2004, 136(6): 1252-1260.
|
[16] |
Dotzenrath C, Cupisti K, Goretzki E, et al. Operative treatment of renal autonomous hyperparathyroidism: cause of persistent or recurrent disease in 304 patients [J]. Langenbecks Arch Surg, 2003, 387(9-10): 348-354.
|
[17] |
张凌,刘亚绵,卞维静,等. 超声引导下甲状旁腺无水酒精注射治疗继发性甲状旁腺功能亢进[J].中华内科杂志,2001, 16 (12): 914-916.
|
[18] |
章建全,仇明,盛建国,等. 超声引导下经皮穿刺热消融治疗甲状旁腺结节[J]. 第二军医大学学报,2013,34(4):362-370.
|
[19] |
中华医学会肾脏病学分会工作组.慢性肾脏病矿物质与骨异常诊治指导[J].中华肾脏病杂志,2014,2(30):S1-S69.
|